Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Loses 2.14% From High. Why That Could Change?

Currently, there are 1.12B common shares owned by the public and among those 1.12B shares have been available to trade.

Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 77,421 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

However, the script later moved the day high at 13.02, up 7.49%. The company’s stock has a 5-day price change of 4.28% and 47.21% over the past three months. TEVA shares are trading 23.66% year to date (YTD), with the 12-month market performance up to 31.47% higher. It has a 12-month low price of $7.09 and touched a high of $12.64 over the same period. TEVA has an average intraday trading volume of 2.29 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.42%, 17.76%, and 38.68% respectively.

Institutional ownership of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) shares accounts for 50.95% of the company’s 1.12B shares outstanding.

It has a market capitalization of $14.47B and a beta (3y monthly) value of 1.03. The earnings-per-share (ttm) stands at -$0.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.63% over the week and 2.98% over the month.

Analysts forecast that Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will achieve an EPS of $0.51 for the current quarter, $0.58 for the next quarter and $2.64 for 2025. The lowest estimate earnings-per-share for the quarter is $0.47 while analysts give the company a high EPS estimate of $0.57. Comparatively, EPS for the current quarter was $0.4 a year ago. Earnings per share for the fiscal year are expected to decrease by -6.63%, and 10.04% over the next financial year. EPS should shrink at an annualized rate of 1.60% over the next five years, compared to 26.63% over the past 5-year period.

Looking at the support for the TEVA, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on Feb-13-24, with the firm’s price target at $12-$19.

Most Popular

Related Posts